Literature DB >> 27798914

miR-21, miR-221 and miR-150 Are Deregulated in Peripheral Blood of Patients with Colorectal Cancer.

Miroslava Sarlinova1, Mirko Halasa2,3, Dusan Mistuna3,4, Ludovit Musak5, Robert Iliev6, Ondrej Slaby6, Jana Mazuchova7, Vanda Valentova8, Lukas Plank9, Erika Halasova10,8.   

Abstract

The Aim of this study was to evaluate the expression levels of miR-21, miR-221, miR-150, let-7a and miR-126a in peripheral blood of 71 patients with colorectal cancer and 80 matched healthy control individuals. We determined expression levels of these microRNAs in peripheral blood samples and used small nucleolar RNA (RNU48) as an internal control. Expression levels of miR-21 (p<0.0001) and miR-221 (p<0.0001) were significantly higher, whereas expression levels of miR-150 (p=0.0054) were significantly lower in the blood samples of patients with colorectal cancer in comparison to the control group. The combination of these three microRNAs enabled us to distinguish patients with colorectal cancer from healthy donors with a sensitivity of 80% and specificity of 74% (p<0.0001). We did not observe any correlation of the studied microRNAs with clinicopathological features of colorectal cancer, indicating that expression of these microRNAs is more likely related to the host response to the tumour than the tumour itself. Copyright
© 2016 International Institute of Anticancer Research (Dr. John G. Delinassios), All rights reserved.

Entities:  

Keywords:  Colorectal cancer; biomarker; miRNA expression; microRNAs

Mesh:

Substances:

Year:  2016        PMID: 27798914     DOI: 10.21873/anticanres.11124

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  8 in total

1.  Expression of Circulating miR-155, miR-21, miR-221, miR-30a, miR-34a and miR-29a: Comparison of Colonic and Rectal Cancer.

Authors:  Enikő Orosz; István Kiss; Zoltán Gyöngyi; Tímea Varjas
Journal:  In Vivo       Date:  2018 Nov-Dec       Impact factor: 2.155

2.  Letter to the editor regarding "Prognostic role of microRNA-150 in various carcinomas: a meta-analysis".

Authors:  Min Li; Ying Yang
Journal:  Onco Targets Ther       Date:  2017-01-13       Impact factor: 4.147

3.  Circulating inflammation signature predicts overall survival and relapse-free survival in metastatic colorectal cancer.

Authors:  Andreas Varkaris; Anastasia Katsiampoura; Jennifer S Davis; Neeraj Shah; Michael Lam; Rosa Lizeth Frias; Cristina Ivan; Masayoshi Shimizu; Jeffrey Morris; David Menter; Michael Overman; Hai Tran; John Heymach; Yun Shin Chun; Jean-Nicolas Vauthey; George Calin; Scott Kopetz
Journal:  Br J Cancer       Date:  2019-01-14       Impact factor: 7.640

4.  Whole Blood Holding Time Prior to Plasma Processing Alters microRNA Expression Profile.

Authors:  Sung Hye Kim; David A MacIntyre; Lynne Sykes; Maria Arianoglou; Phillip R Bennett; Vasso Terzidou
Journal:  Front Genet       Date:  2022-01-14       Impact factor: 4.599

Review 5.  MicroRNAs and 'Sponging' Competitive Endogenous RNAs Dysregulated in Colorectal Cancer: Potential as Noninvasive Biomarkers and Therapeutic Targets.

Authors:  Brian G Jorgensen; Seungil Ro
Journal:  Int J Mol Sci       Date:  2022-02-16       Impact factor: 5.923

6.  The functional mechanism of miR-125b in gastric cancer and its effect on the chemosensitivity of cisplatin.

Authors:  Xinyue Zhang; Jie Yao; Kai Guo; Hu Huang; Siyuan Huai; Rui Ye; Baolong Niu; Tiannan Ji; Weidong Han; Jianxiong Li
Journal:  Oncotarget       Date:  2017-12-14

7.  MicroRNA-150 inhibits the proliferation and metastasis potential of colorectal cancer cells by targeting iASPP.

Authors:  Chen Li; Xiaohui Du; Shaoyou Xia; Lin Chen
Journal:  Oncol Rep       Date:  2018-04-30       Impact factor: 3.906

Review 8.  Novel Diagnostic Biomarkers in Colorectal Cancer.

Authors:  Aneta L Zygulska; Piotr Pierzchalski
Journal:  Int J Mol Sci       Date:  2022-01-13       Impact factor: 5.923

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.